These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34010748)

  • 1. P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression.
    Veldman ER; Mamula D; Jiang H; Tiger M; Ekman CJ; Lundberg J; Svenningsson P
    J Affect Disord; 2021 Jul; 290():240-244. PubMed ID: 34010748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
    Lundin NB; Sepe-Forrest L; Gilbert JR; Carver FW; Furey ML; Zarate CA; Nugent AC
    J Affect Disord; 2021 Jan; 279():239-249. PubMed ID: 33074143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled PET study of ketamine´s effect on serotonin
    Tiger M; Veldman ER; Ekman CJ; Halldin C; Svenningsson P; Lundberg J
    Transl Psychiatry; 2020 Jun; 10(1):159. PubMed ID: 32475989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
    Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
    Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
    Lee CW; Chen YJ; Wu HF; Chung YJ; Lee YC; Li CT; Lin HC
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jul; 93():102-113. PubMed ID: 30940482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
    Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
    Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
    Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
    Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurometabolite changes in response to antidepressant medication: A systematic review of
    Boucherie DE; Reneman L; Ruhé HG; Schrantee A
    Neuroimage Clin; 2023; 40():103517. PubMed ID: 37812859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
    Nugent AC; Ballard ED; Gould TD; Park LT; Moaddel R; Brutsche NE; Zarate CA
    Mol Psychiatry; 2019 Jul; 24(7):1040-1052. PubMed ID: 29487402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
    Nugent AC; Wills KE; Gilbert JR; Zarate CA
    Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
    Lewis V; Rodrigue B; Arsenault E; Zhang M; Taghavi-Abkuh FF; Silva WCC; Myers M; Matta-Camacho E; Aguilar-Valles A
    J Neurochem; 2023 Jul; 166(1):10-23. PubMed ID: 35680556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.
    Singh B; MahmoudianDehkordi S; Voort JLV; Han X; Port JD; Frye MA; Kaddurah-Daouk R;
    Psychiatry Res; 2022 Aug; 314():114655. PubMed ID: 35738038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketamine: Leading us into the future for development of antidepressants.
    Carreno FR; Lodge DJ; Frazer A
    Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine.
    Quintanilla B; Medeiros GC; Greenstein D; Yuan P; Johnston JN; Park LT; Goes FS; Gould TD; Zarate CA
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):89-96. PubMed ID: 36821406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.